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THE SCALE OF THE CHALLENGE
Polypharmacy, usually defined as the 
ongoing use of ≥4 medicines by one person, 
presents one of the most pressing primary 
care challenges of our time. This simple 
definition conceals much of the complexity 
that the concept evokes in the mind of the 
GP. Polypharmacy is not a new challenge 
for general practice, but the scale and 
complexity of the challenge is increasing. 
One Scottish study showed that about 20% 
of adults are dispensed ≥5 drugs (this 
has doubled since 1995) and about 6% of 
adults are dispensed ≥10 drugs (this has 
tripled since 1995).1 The use of 10 drugs 
is regarded as a pragmatic indicator of 
‘high risk’ prescribing and we should all 
be concerned by the rising prevalence of 
this phenomenon, especially in the context 
that 10% of hospital admissions among 
older adults are attributed to adverse 
drug reactions. Polypharmacy is costly 
to the NHS, wasteful (50% of medicines 
prescribed for long-term conditions are 
not used), and prone to error. According 
to the PRACtICe study,2 errors arise in 5% 
of prescription items in general practice. 
Although these are mostly errors of mild 
to moderate severity, one in 550 of these 
errors has the potential to cause severe 
harm. Given the scale of prescribing it 
is clearly an important area in which to 
improve care.
FACTORS DRIVING POLYPHARMACY
There are many factors driving 
polypharmacy. At best polypharmacy 
may be a necessary response to shifting 
demographics and a rising, ageing 
population of patients with multimorbidities; 
above the age of 65 years multimorbidity 
is the norm. At worst, polypharmacy is 
an example of medical overactivity and 
iatrogenic harm. It arises in the context 
of a market-driven approach to health, 
focused on disease-specific, measurable 
standards, incentives, and an insatiable 
desire to eliminate risk and increase 
profits. It seems somewhat ironic that 
one of the factors driving polypharmacy 
— the focus on reducing risk of disease — 
should contribute to this high-risk situation. 
Ueda et al (this issue) estimate that strict 
application of the 2014 National Institute 
for Health and Care Excellence (NICE) 
cholesterol guidelines using the QRISK2 
algorithm would result in 95% of males 
and two-thirds of females without existing 
cardiovascular disease in the age group 
60–74 years, and all males and females in 
the age group 75–84 years, requiring statin 
therapy.3 One of our academic colleagues 
recently referred to polypharmacy as ‘the 
side-effect of evidence-based medicine’. 
Another responded to this with a wry smile 
and remarked, ‘this is entirely a matter 
of perspective; for the pharmaceutical 
industry it is not the side effect, it is the 
effect’ (personal communications, 2016).
Critics of our current predicament argue 
that ‘[c]are that is measurably better may 
be meaningfully worse and a nightmare 
for the patient’ and call for a paradigm shift 
away from a disease-based model to one 
that focuses on care for patients.4 They 
recognise that this may involve complex 
decisions around not prescribing or 
stopping treatments, the evidence for which 
is often missing.4 However, willingness 
to engage in these complex decisions 
is a necessary contribution to reducing 
patients’ considerable burden of treatment. 
The search for evidence to underpin the 
recent NICE guideline on multimorbidity 
illustrates the stark reality of the evidence 
desert: specific recommendations 
regarding stopping medicines were only 
possible for one group of preventive drugs 
(bisphosphonates).5
ADDRESSING THE POLYPHARMACY 
CHALLENGE: WHAT MATTERS TO GPs?
A Dutch study comprising focus groups with 
GPs who discussed case study vignettes 
designed to highlight multimorbidity and 
polypharmacy found that GPs identified 
similar broad strategies for medicines 
management (for example, defining 
treatment goals, adjusting medications 
based on treatment effects) but suggested 
different ways of executing these strategies 
in practice. Participating GPs highlighted 
the value of support from other GPs or 
pharmacists in making these complex 
decisions.6 This finding resonates with the 
work of Sinnott et al, who explored GP 
decision making using in-depth qualitative 
interviews incorporating case-specific 
chart-stimulated recall.7 GPs’ accounts of 
their decision making revealed a process 
of ‘satisficing’, that is, accepting care that 
is satisfactory and sufficient in the context 
of the particular patient. ‘Satisficing’ was 
a process of negotiating and accepting 
compromise, relaxing targets for disease 
control, and making best guesses about 
the most appropriate course of action. This 
sometimes meant accepting the status quo 
in situations regarded as stable, even if this 
entailed significant ongoing polypharmacy. 
Proactive changes to medication were 
most likely in the context of continuity of 
care, ample consultation time, and open 
communication with the patient, other 
health professionals, and GPs.7 These 
conditions are increasingly under threat 
in an overstretched NHS where relational 
continuity with a GP is difficult to sustain, and 
this may compound attempts to address 
the polypharmacy challenge. GPs’ sense 
of isolation was an overarching theme in 
Sinnott et al’s meta-ethnographic synthesis 
of qualitative research investigating GPs’ 
experience of caring for patients with 
multimorbidity.8 The researchers have 
now incorporated this important finding 
into a complex intervention that involves 
collaborative medication review by two GPs 
using a short medication checklist; this 
intervention has the notion of collegial peer 
support at its centre.9
ADDRESSING THE POLYPHARMACY 
CHALLENGE: WHAT MATTERS TO 
PATIENTS?
Although polypharmacy is increasingly 
recognised as problematic, the capacity to 
reconfigure care to adapt to the complex 
realities of patients’ lives is limited in part by 
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our poor understanding of what matters to 
patients. Although ‘medicines optimisation’ 
— a person-centred approach to safe and 
effective medicines use — is a laudable goal, 
there has been little research exploring 
patients’ perspectives and priorities around 
medicine taking, nor their actual experience 
and practices of fitting medicines into their 
daily lives and their varying capacity to do 
this. Interest in this area is increasing. 
One study comprising questionnaire and 
interview data gathered in the context of 
the OPTI-SCRIPT randomised controlled 
trial found that, although 96% of patients 
believed strongly in the necessity of their 
medications, 34% also reported strong 
concerns about the potential for adverse 
consequences.10 The importance of 
interpersonal trust between patient and 
doctor emerged as an important element 
of patients’ ability to manage this uncertain 
situation.10
A recent pilot study conducted across 
14 Dutch general practices (17 GPs) 
and including 59 older patients with 
multimorbidity who were prescribed ≥5 
medications investigated the use of a 
simple outcome prioritisation tool (www.
optool.nl). In the context of a consultation 
with their GP, patients were invited to 
express their preferences across four 
priorities: remaining alive; maintaining 
independence; reducing pain; and reducing 
other symptoms.11 This formed the basis 
for a conversation about their medication. 
Although this was a small pilot study, 
the researchers found that most of the 
medication changes made (34 changes, 
involving 20 patients) involved either 
reducing drug doses or stopping them 
altogether. The use of such prioritisation 
tools may represent a promising way 
forward. 
CONCLUSION
Kaufman, reflecting on the quandary 
of crossing the line towards too much 
medicine in the care of older people, 
writes: ‘although few appear to have 
foreseen our current predicament, it was 
inevitable that medicine would collide 
with age’.12 Polypharmacy is a ‘wicked’ 
problem comprising a complex tangle of 
the biological, behavioural, technological, 
cultural, and sociopolitical. It is unlikely 
that GPs can address the challenge single-
handedly, because the solutions to some of 
these factors lie in higher-order structural, 
economic, and sociopolitical change. 
But there is much work we can do. The 
terms ‘appropriate’ and ‘inappropriate’ as 
applied to polypharmacy might benefit from 
some unpacking: ‘appropriate to whom?’ 
and ‘appropriate for what purpose or with 
what in mind?’
There is much scope for investigating how 
patients, carers, doctors, and other health 
professionals negotiate polypharmacy, 
medicines optimisation, and deprescribing 
in their day-to-day lives and practices. 
This needs to include attention to some 
of the most complex situations, such as 
negotiating decisions when patients do not 
have the mental capacity to take part in such 
decision making themselves. Opportunities 
for working in new and innovative ways 
with our pharmacy colleagues (the 
accompanying editorial by Avery, this 
issue)13 may provide hopeful ways forward, 
as may closer involvement of patients and 
carers — not only in their own management 
but also in setting the research agenda 
moving forward. It is quite possible that 
polypharmacy presents primary care with 
an opportunity to assert its commitment 
to generalism, to re-focus on the patient-
as-person and the professional-as-person, 
and to grapple effectively with complexity 
in practice. It is also possible that we may 
achieve more health with less medicine.
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